PMID: 9433338Jan 20, 1998Paper

Haloperidol plasma levels and dose optimization

The American Journal of Psychiatry
W CoryellP J Perry

Abstract

This study was designed to test the practical utility of haloperidol plasma level determinations in the management of schizophrenic patients who show poor initial responses to haloperidol. Inpatients with acute exacerbations of DSM-III schizophrenia (N = 66) were randomly assigned to receive fixed haloperidol doses intended to achieve plasma levels of 8-18 ng/ml or of 25-35 ng/ml. Patients whose scores on the Brief Psychiatric Rating Scale (BPRS) failed to improve by at least 30% at the end of 3 weeks were then subject to dose reassignment. Among the patients who completed the first phase of the protocol, 30 had steady-state haloperidol plasma levels of less than 18 ng/ml, and 22 had levels that exceeded 25 ng/ml; 14 had intermediate plasma levels of 18-25 ng/ml. A survival analysis of time to 30% improvement significantly favored the two lower plasma level groups, although side effect ratings did not differ. Of the 30 patients whose BPRS scores failed to improve by 30% after 3 weeks, 11 and five were randomly assigned to receive lower and higher doses, respectively. Those whose dose was lowered experienced significantly more improvement in the subsequent weeks than did those whose dose was increased. Haloperidol plasma levels ...Continue Reading

Citations

Sep 22, 2005·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Peter FalkaiUNKNOWN WFSBP Task Force on Treatment Guidelines for Schizophrenia
Dec 8, 2009·Journal of Psychiatric Research·Ina GieglingAlessandro Serretti
Jan 21, 2006·Acta Psychiatrica Scandinavica·R M CarnahanE A Chrischilles
Mar 30, 2016·Pharmacogenomics·Stefano PorcelliDan Rujescu
Aug 16, 2011·Progress in Neuro-psychopharmacology & Biological Psychiatry·Andréa L SertiéWagner F Gattaz
Oct 2, 2003·The Annals of Pharmacotherapy·Stanford S JheeSteve J Sims
Jan 5, 2002·Journal of Psychopharmacology·P OosthuizenN Keyter
Nov 30, 2016·Translational Psychiatry·E KristófL Fésüs
May 12, 2018·The Cochrane Database of Systematic Reviews·Myrto T SamaraStefan Leucht
Jun 23, 2004·Journal of Clinical Psychopharmacology·John M Davis, Nancy Chen
Aug 29, 2013·The Cochrane Database of Systematic Reviews·Lorna DonnellyClive E Adams
Jan 22, 2019·Bioanalysis·Maria Eugênia Costa QueirozJaime E Cecilio Hallak
Nov 15, 2012·Therapeutic Drug Monitoring·Lisbeth PatteetHugo Neels
Jan 27, 2006·The Cochrane Database of Systematic Reviews·R G MarriottS Waddingham

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Journal of Neuropsychiatry
L E HOLLISTER, F P MOTZENBECKER
Advances in Biochemical Psychopharmacology
P L MorselliP Deniker
Psychopharmacology Bulletin
T Van PuttenR P O'Brien
© 2021 Meta ULC. All rights reserved